Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
Biomarker
Drug-induced liver injury
Hepatocellular carcinoma
Magnetic resonance elastography
Sorafenib
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
08
06
2020
accepted:
25
09
2020
revised:
25
08
2020
pubmed:
10
10
2020
medline:
15
4
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
We investigated whether liver stiffness (LS) quantified using magnetic resonance elastography (MRE) could predict the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib. We selected 50 sorafenib-treated advanced HCC patients who underwent MRE within 3 months before drug administration from a prospectively maintained cohort of chronic liver disease patients, according to the inclusion and exclusion criteria. Univariate and multivariate analyses were performed to evaluate the prognostic role of laboratory data, tumor characteristics, and MRE-assessed LS for overall survival (OS), progression-free survival (PFS), and significant liver injury (grade ≥ 3) after sorafenib administration. High MRE-assessed LS either as continuous (per kPa, hazard ratio (HR) 1.54; 95% confidence interval (CI) 1.23-1.92, p < 0.001) or categorical (> 7.5 kPa, HR 4.06, 95% CI 1.40-11.79, p < 0.01) variable was significantly associated with poor OS along with higher serum alpha-fetoprotein (AFP, ≥ 400 ng/mL) and advanced tumor stage (modified Union for International Cancer Control (mUICC) IVb). Higher MRE-assessed LS was also significantly associated with the development of significant liver injury after sorafenib administration (per kPa, HR 1.62, 95% CI 1.21-2.17, p = 0.001; > 7.5 kPa, HR 10.11, 95% CI 2.41-42.46, p = 0.002). PFS analysis identified higher serum AFP (≥ 400 ng/mL) and advanced tumor stage (mUICC IVb) as significant risk factors for early disease progression, whereas LS was not associated with PFS CONCLUSION: Higher MRE-assessed LS is a potential biomarker for predicting poor OS and significant liver injury in advanced HCC patients treated with sorafenib. • Higher pretreatment LS by MRE (> 7.5 kPa), higher AFP (≥ 400 ng/mL), and advanced tumor stage (mUICC IVb) were associated with poor OS in advanced HCC patients treated with sorafenib. • Higher pretreatment LS by MRE was associated with developing significant (grade ≥ 3) liver injury during sorafenib treatment, which required termination of the therapy. • Patients with high pretreatment LS by MRE should be monitored carefully for potential liver injury during sorafenib treatment.
Identifiants
pubmed: 33033862
doi: 10.1007/s00330-020-07357-9
pii: 10.1007/s00330-020-07357-9
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2507-2517Subventions
Organisme : National Research Foundation of Korea
ID : NRF- 2018M3A9E8023861
Références
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
doi: 10.1056/NEJMoa0708857
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
doi: 10.3322/caac.21492
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750
doi: 10.1002/hep.29913
Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v59–v64
doi: 10.1093/annonc/mdq166
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
doi: 10.1055/s-2007-1007122
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
doi: 10.1016/S1470-2045(08)70285-7
Adnane L, Trail PA, Taylor I, Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597–612
doi: 10.1016/S0076-6879(05)07047-3
National Institute of Diabetes and Digestive and Kidney Diseases (2020) LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda Available via https://livertox.nih.gov/ . Accessed 25 April 2020
Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W (2016) Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open 1:e000042
doi: 10.1136/esmoopen-2016-000042
Mariappan YK, Glaser KJ, Ehman RL (2010) Magnetic resonance elastography: a review. Clin Anat 23:497–511
doi: 10.1002/ca.21006
Wang QB, Zhu H, Liu HL, Zhang B (2012) Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology 56:239–247
doi: 10.1002/hep.25610
Cho HJ, Kim B, Kim HJ et al (2020) Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. Eur Radiol 30:4182–4192
doi: 10.1007/s00330-020-06792-y
Lee DH, Lee JM, Chang W et al (2018) Prognostic role of liver stiffness measurements using magnetic resonance elastography in patients with compensated chronic liver disease. Eur Radiol 28:3513–3521
doi: 10.1007/s00330-017-5278-x
Ichikawa S, Motosugi U, Enomoto N, Onishi H (2019) Magnetic resonance elastography can predict development of hepatocellular carcinoma with longitudinally acquired two-point data. Eur Radiol 29:1013–1021
doi: 10.1007/s00330-018-5640-7
Kim HJ, Kim B, Yu HJ et al (2020) Reproducibility of hepatic MR elastography across field strengths, pulse sequences, scan intervals, and readers. Abdom Radiol (NY) 45:107–115
doi: 10.1007/s00261-019-02312-9
Ayuso C, Rimola J, Vilana R et al (2018) Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 101:72–81
doi: 10.1016/j.ejrad.2018.01.025
Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263
doi: 10.3350/cmh.2018.0090
Kim MY, Baik SK, Lee SS (2010) Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 16:347–352
doi: 10.3350/kjhep.2010.16.4.347
Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H (2015) Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol 7:406–424
doi: 10.4254/wjh.v7.i3.406
Lee JS, Choi HJ, Kim BK et al (2020) The modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver. https://doi.org/10.5009/gnl19197
National Cancer Institute (2020) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute. Available via https://evs.nci.nih.gov/ . Accessed 25 April 2020
National Institute of Diabetes and Digestive and Kidney Diseases (2019) Severity grading in drug induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. Available via https://www.ncbi.nlm.nih.gov/books/NBK548241/ . Accessed 25 April 2020
Ozenne V, Paradis V, Pernot S et al (2010) Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 22:1106–1110
doi: 10.1097/MEG.0b013e3283386053
Ogasawara S, Kanai F, Obi S et al (2011) Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5:850–856
doi: 10.1007/s12072-010-9249-4
Federico A, Orditura M, Cotticelli G et al (2015) Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett 9:1628–1632
doi: 10.3892/ol.2015.2960
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) (2018) 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 20:1042–1113
doi: 10.3348/kjr.2019.0140
Kim SU, Ahn SH, Park JY et al (2008) Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. Hepatol Int 2:471–477
doi: 10.1007/s12072-008-9091-0
Poon RT, Fan ST, Lo CM et al (2002) Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 236:602–611
doi: 10.1097/00000658-200211000-00010
Lee DH, Lee JM, Yi NJ et al (2017) Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma. Eur Radiol 27:1713–1721
doi: 10.1007/s00330-016-4499-8
Jang S, Lee JM, Lee DH et al (2017) Value of MR elastography for the preoperative estimation of liver regeneration capacity in patients with hepatocellular carcinoma. J Magn Reson Imaging 45:1627–1636
doi: 10.1002/jmri.25517
Thompson SM, Wang J, Chandan VS et al (2017) MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features—preliminary findings. Magn Reson Imaging 37:41–45
doi: 10.1016/j.mri.2016.11.005
Qayyum A, Hwang K-P, Stafford J et al (2019) Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer 7:329
doi: 10.1186/s40425-019-0766-y
Trout AT, Serai S, Mahley AD et al (2016) Liver stiffness measurements with MR elastography: agreement and repeatability across imaging systems, field strengths, and pulse sequences. Radiology 281:793–804
doi: 10.1148/radiol.2016160209